Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension.
NOVEL THERAPEUTIC DRUGS THAT INHIBIT NLRP3 INFLAMMASOMES TO TREAT INFLAMMATORY DISEASES, WITH A PRIMARY FOCUS ON PULMONARY ARTERIAL HYPERTENSION (PAH)